A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Veracyte, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 23,200 shares of VCYT stock, worth $866,288. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,200
Previous 8,700 166.67%
Holding current value
$866,288
Previous $192,000 161.46%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$18.86 - $23.55 $140,280 - $175,164
-7,438 Reduced 13.5%
47,642 $1.03 Million
Q1 2024

May 15, 2024

SELL
$21.0 - $29.1 $13.6 Million - $18.9 Million
-649,032 Reduced 92.18%
55,080 $1.22 Million
Q4 2023

Feb 14, 2024

SELL
$19.72 - $28.68 $143,344 - $208,474
-7,269 Reduced 1.02%
704,112 $19.4 Million
Q3 2023

Nov 14, 2023

BUY
$22.33 - $29.92 $11.2 Million - $15.1 Million
503,449 Added 242.12%
711,381 $15.9 Million
Q2 2023

Aug 14, 2023

SELL
$20.96 - $26.99 $19.6 Million - $25.2 Million
-934,459 Reduced 81.8%
207,932 $5.3 Million
Q1 2023

May 15, 2023

BUY
$20.58 - $27.89 $12.2 Million - $16.5 Million
591,907 Added 107.52%
1,142,391 $25.5 Million
Q4 2022

Feb 14, 2023

BUY
$15.31 - $29.94 $2.21 Million - $4.33 Million
144,559 Added 35.61%
550,484 $13.1 Million
Q3 2022

Nov 14, 2022

BUY
$16.58 - $27.9 $2.02 Million - $3.4 Million
121,788 Added 42.86%
405,925 $6.74 Million
Q2 2022

Aug 15, 2022

BUY
$15.45 - $29.52 $1.67 Million - $3.18 Million
107,769 Added 61.1%
284,137 $5.66 Million
Q1 2022

May 16, 2022

BUY
$21.94 - $42.51 $789,181 - $1.53 Million
35,970 Added 25.62%
176,368 $4.86 Million
Q4 2021

Feb 14, 2022

SELL
$36.09 - $53.79 $4.18 Million - $6.22 Million
-115,698 Reduced 45.18%
140,398 $5.78 Million
Q3 2021

Nov 15, 2021

BUY
$35.62 - $52.97 $881,844 - $1.31 Million
24,757 Added 10.7%
256,096 $11.9 Million
Q2 2021

Aug 16, 2021

BUY
$32.94 - $56.62 $3.89 Million - $6.69 Million
118,122 Added 104.33%
231,339 $9.25 Million
Q1 2021

May 17, 2021

BUY
$44.47 - $81.38 $4.58 Million - $8.38 Million
103,032 Added 1011.61%
113,217 $6.09 Million
Q4 2020

Feb 16, 2021

SELL
$32.49 - $61.88 $2.82 Million - $5.36 Million
-86,680 Reduced 89.49%
10,185 $498,000
Q3 2020

Nov 16, 2020

BUY
$26.73 - $35.67 $2.59 Million - $3.46 Million
96,865 New
96,865 $3.15 Million
Q2 2020

Aug 14, 2020

SELL
$19.49 - $28.11 $361,929 - $522,002
-18,570 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$16.13 - $30.17 $299,534 - $560,256
18,570 New
18,570 $451,000
Q4 2019

Feb 14, 2020

SELL
$20.78 - $29.99 $1.45 Million - $2.1 Million
-69,922 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$23.87 - $30.93 $308,615 - $399,893
12,929 Added 22.69%
69,922 $1.68 Million
Q2 2019

Aug 14, 2019

SELL
$22.1 - $28.56 $3.38 Million - $4.36 Million
-152,776 Reduced 72.83%
56,993 $1.63 Million
Q1 2019

May 15, 2019

BUY
$12.0 - $25.76 $279,528 - $600,053
23,294 Added 12.49%
209,769 $0
Q4 2018

Feb 14, 2019

BUY
$9.15 - $14.85 $747,866 - $1.21 Million
81,734 Added 78.03%
186,475 $2.35 Million
Q3 2018

Nov 13, 2018

BUY
$9.55 - $12.64 $893,526 - $1.18 Million
93,563 Added 837.03%
104,741 $0
Q1 2018

May 11, 2018

SELL
$5.44 - $6.97 $424 - $543
-78 Reduced 0.69%
11,178 $62,000
Q4 2017

Feb 09, 2018

BUY
$6.05 - $9.37 $68,098 - $105,468
11,256
11,256 $74,000

Others Institutions Holding VCYT

About VERACYTE, INC.


  • Ticker VCYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,575,904
  • Market Cap $2.67B
  • Description
  • Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...
More about VCYT
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.